A perspective on the widening gap between Covishield vaccine doses in India
Indian Journal of Community Health
; 33(3):541-542, 2021.
Article
Dans Anglais
| CAB Abstracts | ID: covidwho-1623067
ABSTRACT
The Oxford University-AstraZeneca's vector-based vaccine called Covishield (ChAdOx1 nCoV- 19 Vaccine) is being manufactured and distributed by Serum Institute of India (SII). National roll out of this vaccine was in a phased manner starting from 16th January 2021. At present, many states are facing shortage of vaccines. Government of India kept changing its policy on dosing gap of Covishield vaccine based on researches. The latest recommendation citing "real-life evidence" from the UK is to extend the two doses of Covishield to 12-16 weeks. This reasonable approach will not only a breathing space for the government but also aids in free up doses for a larger number of people to get their first dose of the vaccine.
Prion, Viral, Bacterial, and, Fungal, Pathogens, of, Humans, [VV210]; Host, Resistance, and, Immunity, [HH600]; vaccines; human, diseases; vaccination; disease, prevention; immunization; coronavirus, disease, 2019; viral, diseases; immune, sensitization; man; Severe, acute, respiratory, syndrome, coronavirus, 2; India; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Commonwealth, of, Nations; lower-middle, income, countries; medium, Human, Development, Index, countries; South, Asia; Asia; Severe, acute, respiratory, syndrome-related, coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense, ssRNA, Viruses; ssRNA, Viruses; RNA, Viruses; viruses; SARS-CoV-2; viral, infections
Texte intégral:
Disponible
Collection:
Bases de données des oragnisations internationales
Base de données:
CAB Abstracts
Les sujets:
Vaccins
langue:
Anglais
Revue:
Indian Journal of Community Health
Année:
2021
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS